Please note, training dates are now available for the STAMPEDE General Site CRF training sessions. These sessions are mainly tailored for new staff members at site and any members wanting refresher training.

We will be discussing, how best to complete the CRFs in order to avoid queries, addressing common errors with CRF completion and responding to Data Clarification Forms.

The training dates are as follows:



11th December 2017 (Monday)

  3pm  –  4.15pm

22nd January 2018 (Monday)

 11am – 12.15pm

More training sessions coming up in the new year, dates to be confirmed.

Please register via Eventbrite using the following link:

You can find the slides for the CRF training here.

Further details on how to dial in via WebEx, will be sent out prior to each training sessions taking place.

On Wednesday 1 November 2017, we'll be running a Twitter Q&A session about the STAMPEDE trial - with the hashtag #BeatProstateCancer. The purpose of the Twitter Q&A is to raise awareness of prostate cancer research. We hope to highlight how the STAMPEDE trial is improving the way in which prostate cancer is managed, enabling men to live longer and enjoy a better quality of life. Prostate cancer accounts for around one fifth of all male cancers. In the UK there are around 47,000 new cases each year and around 10,800 deaths. Most men with prostate cancer are given hormone therapy and this is often effective for a short time at stopping the tumour growing. However in most cases over time the tumour will start to grow again. The aim of this trial is to try to prevent the tumour re-growth by adding other treatment to the hormone therapy. STAMPEDE is testing several new treatments, compared to the standard treatment used for prostate cancer. So far, STAMPEDE has released results ...

As you have found, STAMPEDE's new updated website has launched. This website is a tool for stakeholders of the STAMPEDE research, assisting in such aspects as the provision of information, running of the trial and the dissemination of results.   Browse the tabs and understand what is just a click away. Don't forget to check regularly for updates and keep us in your favourites! ...

The latest results from the Stampede trial in prostate cancer look to confirm a seismic shift in the treatment landscape in favour of Johnson & Johnson’s ageing Zytiga, but the impact for the whole industry – following a study run by academics – could be even more significant.

Check out the latest press, resulting from STAMPEDEs presentations across the European Society for Medical Oncology (ESMO) conference, through the EPVantage link below!


Results of a systematic review including two large trials have confirmed that adding a drug called abiraterone to standard long-term hormone therapy helps men with prostate cancer that has spread to live longer. These results, from the STOPCaP study, were published this week in the European Journal of Cancer. Abiraterone is a type of hormone therapy currently licensed to treat prostate cancer that has spread and has stopped responding to standard hormone therapy. Both trials tested using it earlier, in men starting long-term standard hormone therapy for the first time. Overall, the results showed that adding abiraterone to standard hormone therapy reduced the risk of death by 38%. This means that after three years, 69 out of 100 men who received abiraterone were alive compared to 55 out of 100 men who just had standard hormone therapy. Abiraterone also reduces the risk of prostate cancer getting worse by 55%. This means that after three years, 58 out of 100 men who received abirater ...


Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.